Latest News and Press Releases

BOSTON and ZUG, Switzerland and CAMBRIDGE, Mass., May 30, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the...

ZUG, Switzerland and CAMBRIDGE, Mass., May 15, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...

-On track to begin CTX001 clinical study in hemoglobinopathies in 2018--On track to file IND in 2018 for CTX101, allogeneic CRISPR-based CAR-T targeted toward CD19+ malignancies--$341.8 million in...

ZUG, Switzerland and CAMBRIDGE, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based...

-Off-the-shelf CAR-T candidates against BCMA and CD70 address both hematologic malignancies and solid tumors - -New data demonstrate high editing rates, consistent expression, selective and potent...

ZUG, Switzerland and CAMBRIDGE, Mass., April 13, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...

ZUG, Switzerland and CAMBRIDGE, MA., April 04, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...

ZUG, Switzerland and CAMBRIDGE, Mass., March 26, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for...

- On track to begin first company-sponsored clinical trials of a CRISPR-based therapy -- Wholly-owned CRISPR-based allogeneic CAR-T programs advancing rapidly - ZUG, Switzerland and CAMBRIDGE, Mass.,...

ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 21, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a genome editing company focused on creating transformative medicine for...